Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT00097708 | Experimental Medication For the Treatment of Generalized Anxiety Disorder | PHASE3 | COMPLETED | 511 | — | — | Nov 1, 2004 | Dec 1, 2005 | Oct 3, 2014 | 50 | United States |
Hamilton Anxiety Rating Scale (HAM-A). Each of 14 symptoms categories is rated from 0=not present to 4=very severe. Numbers for all categories are summed to produce the total score. Total score ranges from 0=anxiety symptoms not present to 56=very severe anxiety symptoms across all 14 categories.
| Name | Type | Description |
|---|---|---|
| experimental anti-anxiety drug | DRUG | - |
Inclusion Criteria: * Subjects 18 to 65 years of age will be eligible to participate if they satisfy the DSM-IV-TR criteria for the diagnosis of GAD. Exclusion Criteria: * No other primary psychiatric diagnosis besides GAD.